Improved outcome of adult acute lymphoblastic leukaemia by moderately intensified chemotherapy which includes a ‘pre‐induction’ course for rapid tumour reduction: preliminary results on 66 patients
Authors:
- van ImhoffVIvan Imhoff
- van Den BergVBvan Den Berg
- de KamDKde Kam
- Haaxma‐ ReicheHRHaaxma‐ Reiche
- E VellengaEVE Vellenga
- J W SmitJSJ W Smit
- R M HalieRHR M Halie
- 1 February 1998
- journal article
- clinical trial
- Published by Wiley in British Journal of Haematology
- Vol. 100 (2) , 273-282
Abstract
Sixty‐six consecutive adult patients with acute lymphoblastic leukaemia (ALL) were treated with intensified chemotherapy which included a ‘pre‐induction’ course of cytarabine (AraC) and etoposide (VP16) when the white blood cell count (WBC) was ≥30 × 109/l (18 patients), and maintenance chemotherapy with regular intensifications for a total treatment duration of 3 years. Patients with a mediastinal mass (17) received consolidation courses with intermediate‐dose AraC and VP16 followed by mediastinal irradiation. 11 patients underwent allogeneic bone marrow transplantation in first complete remission (CR). 58 patients (87.9%, CI 77.5–94.6) attained CR; with a median follow‐up of 7 years, 35 of them (60.3%, CI 46.6–73.0) remain in CR. Toxicity was mild, although three patients died during remission induction, including two who were over 70 years of age. 23 patients (39.7%, CI 27.1–53.4) relapsed, seven of them primarily in the central nervous system (CNS), necessitating intensification of CNS‐directed therapy. Only one of 13 patients with WBC 30–100 × 109/l, but eight of nine with WBC >100 × 109/l, relapsed. The survival of older patients in CR did not differ from younger patients. The outcome of ALL in adult patients could thus be improved by slight intensification of treatment whilst keeping the toxicity within acceptable limits. ‘Pre‐induction’ with AraC and VP16 might improve the prognosis, especially in patients with WBC 100 × 109/l, however, almost always relapse, and the intensified chemotherapy might not be tolerated well by patients over 70 years of age.Keywords
This publication has 30 references indexed in Scilit:
- Abstracts of papers presented at the Second Meeting of the European Haematology Association, Paris, France, 29 May‐1 June 1996British Journal of Haematology, 1996
- Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12 000 randomised childrenThe Lancet, 1996
- High efficacy of the German multicenter ALL (GMALL) protocol for treatment of adult acute lymphoblastic leukemia (ALL) — a single-institution studyAnnals of Hematology, 1994
- Acute lymphocytic leukaemia in the elderly: characteristics and outsome with the vincristine‐adriamycin‐dexamethasone (VAD) regimenBritish Journal of Haematology, 1994
- Estimatetd 8‐year survival of more than 40% in a population‐based study of 79 adult patients with acute lymphoblastic leukaemiaBritish Journal of Haematology, 1994
- Intensive induction/consolidation therapy without maintenance in adult acute lymphoblastic leukaemia: a pilot assessmentBritish Journal of Haematology, 1994
- Acute Myeloid Leukemia in Children Treated with Epipodophyllotoxins for Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 1991
- Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapyThe Lancet, 1991
- Six-year follow-up of the clinical significance of karyotype in acute lymphoblastic leukemiaCancer Genetics and Cytogenetics, 1989
- Acute lymphoblastic leukemia in adults: Results of intraventricular maintenance chemotherapy for central nervous system prophylaxis and treatmentEuropean Journal of Cancer and Clinical Oncology, 1988